• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Mavelertinib Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5756700

Mavelertinib is an orally available inhibitor of the EGFR mutant form T790M, a secondarily acquired resistance mutation. Mavelertinib specifically binds to and inhibits EGFR T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFR… More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Mavelertinib, Inhibitor
Full Product Name
Mavelertinib
Product Synonym Names
PF 6747775; PF6747775; PF 06747775; PF06747775; PF06747775
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
415.43
Solubility
Water: Insoluble
DMSO: Soluble
(<1mg/ refers to the product slightly soluble or insoluble)
Formula
C18H22FN9O2
SMILES
C=CC(N[C@@H]1CN(C2=NC(NC3=CN(C)N=C3OC)=C4N=CN(C)C4=N2)C[C@H]1F)=O
CAS Number
1776112-90-3

Product References and Citations for Mavelertinib, inhibitor

Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens MD, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine JA. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) Through Structure-Based Drug Design; A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants With Selectivity Over Wild-Type EGFR. J Med Chem. 2017 Mar 13. doi: 10.1021/acs.jmedchem.6b01894. [Epub ahead of print] PubMed PMID: 28287730.
Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016 Apr 12;9:34. doi: 10.1186/s13045-016-0268-z. Review. PubMed PMID: 27071706; PubMed Central PMCID: PMC4830020.

Other Notes

Small volumes of Mavelertinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Mavelertinib purchase

MBS5756700 is an inhibitor targeting Mavelertinib.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000